A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study | Zendy

Weerawat Manosuthi | Zendy; Somnuek Sungkanuparph | Zendy; Preecha Tantanathip | Zendy; Aroon Lueangniyomkul | Zendy; Wiroj Mankatitham | Zendy; Wisit Prasithsirskul | Zendy; Sunantha Burapatarawong | Zendy; Supeda Thongyen | Zendy; Sirirat Likasakul | Zendy; Unchana Thawornwa | Zendy; Vilaiwan Prommool | Zendy; Kiat Ruxrungtham | Zendy

Open Access

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N₂R Study

Author(s) -

Weerawat Manosuthi,

Somnuek Sungkanuparph,

Preecha Tantanathip,

Aroon Lueangniyomkul,

Wiroj Mankatitham,

Wisit Prasithsirskul,

Sunantha Burapatarawong,

Supeda Thongyen,

Sirirat Likasakul,

Unchana Thawornwa,

Vilaiwan Prommool,

Kiat Ruxrungtham

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/599114

Subject(s) - nevirapine , efavirenz , medicine , reverse transcriptase inhibitor , rifampicin , randomized controlled trial , gastroenterology , odds ratio , confidence interval , viral load , tuberculosis , pharmacology , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , pathology

To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research